Oncolytics Biotech adds Cochrane to board
2002-11-06 05:48 PT - News Release
Ms. Cathy Ward reports
ONCOLYTICS BIOTECH APPOINTS DR. WILLIAM A. COCHRANE TO THE BO ...
Oncolytics Biotech has appointed William A. Cochrane, MD, to the board of directors.
"Dr. Cochrane brings additional depth to our board of directors," said Dr. Brad Thompson, president and chief executive officer of Oncolytics. "His extensive experience spans sectors including the pharmaceutical and biotechnology industries, finance, academia and medicine. We expect the company will benefit significantly from his contributions to the board."
Dr. Cochrane is currently the chairman of Stressgen Biotechnologies Corporation, president of W.A. Cochrane & Associates Inc., chairman of UTI at the University of Calgary, and serves on the boards of a number of Canadian and American companies. Previously, Dr. Cochrane was the CEO and chairman of Connaught Laboratories Ltd. He has also served as the Deputy Minister of Health Services for the Province of Alberta, and president and vice-chancellor, and dean of medicine at the University of Calgary. He has served on the boards of MDS Capital Corp., Connaught Laboratories Ltd., Monsanto Canada Inc. and Fluor/Daniel Canada Inc. Dr. Cochrane is an officer of the Order of Canada, a 2002 recipient of the Queen's Golden Jubilee Medal for his many contributions to Canada, and received his MD from the University of Toronto.
"I am pleased to be involved with Oncolytics at this point in its development," said Dr. Cochrane. "I look forward to assisting the company reach its goal of developing Reolysin as a potential cancer therapeutic." |
